drugset
drugset / Trial / NCT04527718

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

NCT04527718 ↗

Phase 1 Completed 40 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1 randomized, double blinded, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of 611 in healthy volunteers.

Timeline

Start
2020-09-09
Primary completion
2021-08-13
Completion
2021-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject 611 Unknown 45 mg Subcutaneous
Subject 611 Unknown 150 mg Subcutaneous
Subject 611 Unknown 300 mg Subcutaneous
Subject 611 Unknown 450 mg Subcutaneous
Subject 611 Unknown 600 mg Subcutaneous

Indications

No indication recorded.